| 1. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 2-2
&NA;,
Preview
|
PDF (832KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 2. |
‘Disturbing’variations in use of adjuvant tamoxifen |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 3-3
&NA;,
Preview
|
PDF (712KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 3. |
Guidelines for the treatment of children with HIV infection |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 4-4
&NA;,
Preview
|
PDF (751KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 4. |
Warfarin prophylaxis justified in nonvalvular AF |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 5-5
&NA;,
Preview
|
PDF (689KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 5. |
Persistence with lipid-lowering therapy in US and Canada |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 6-6
&NA;,
Preview
|
PDF (583KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 6. |
Mibefradilin a class of its own and saving on costs |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 7-8
Wayne Elwood,
Preview
|
PDF (1495KB)
|
|
摘要:
The cost of treating patients with hypertension is estimated to be a staggering $US2 billion/year in the US. Potentially, this figure could soar even higher, according to information from the National Center for Health Statistics that suggests about 50 million Americans have high BP, but that this is only adequately controlled in 12 million patients. Clinical trials are required to demonstrate efficacy and tolerability before any new drug can gain regulatory approval. However, this information may not be sufficient to gain formulary approval. Most managed care organisations now also want to see outcomes data as part of their decision making process. In this respect, ‘real-life’ data, derived from actual practice settings are needed. Results from the first prospective, head-to-head study of treatment costs in patients with hypertension were reported at the 10th Annual Meeting of the National Managed Health Care Congress [Atlanta, US; April 1998]. This naturalistic outcomes study compared calcium antagonist therapy with either mibefradil [‘Posicor’] or the current gold-standard agent, amlodipine [‘Norvasc’].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 7. |
Potential vaccine forS. aureusinfection |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 8-8
&NA;,
Preview
|
PDF (736KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 8. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 9-9
&NA;,
Preview
|
PDF (722KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 9. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 10-10
&NA;,
Preview
|
PDF (677KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 10. |
Fomivirsen focuses on the future in CMV retinitis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1138,
1998,
Page 11-12
Sean Henahan,
Preview
|
PDF (1530KB)
|
|
摘要:
Fomivirsen, a novel treatment for sight-threatening cytomegalovirus (CMV) retinitis, is on track to become the first antisense agent to make it to the clinic. Infection with CMV, a herpesvirus, is generally asymptomatic in immunocompetent individuals. However, CMV retinitis is among the most common opportunistic infections seen in patients with HIV infection. It typically occurs late in the disease and can cause blindness. Researchers reported favourable results with fomivirsen [Isis Pharmaceuticals] in a phase III clinical trial in patients with advanced, refractory CMV retinitis, at the 11th Conference of the International Society for Antiviral Research [San Diego, US; April 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
首页
